跳到正文
原文
BioPharma Dive· Susan Kelly·· 2026-10-06AI 评分40

GE HealthCare 以 9.45 亿美元收购 Sofie Biosciences

GE HealthCare to acquire Sofie Biosciences for $945M

AI 导读

GE HealthCare 宣布以 9.45 亿美元现金收购 CRO 企业 Sofie Biosciences,以拓展美国放射性药物制造能力。交易预计于 2027 年上半年完成,Sofie Biosciences 将加入 GE HealthCare 的 PDx 业务部门。此次收购使 GE HealthCare 获得 15 个美国 CMO 站点,旨在解决 PET 放射性药物供应瓶颈。

正文

An article from site logo

Dive Brief

The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.

Published Oct. 6, 2026

By

A scientist in white jacket operates radiopharmaceutical manufacturing equipment.

Sofie Biosciences has 15 CMO sites across the U.S. manufacturing PET radiopharmaceutical products. Courtesy of GE HealthCare

First published on

MedTech Dive

Dive Brief:

  • GE HealthCare said Monday it has agreed to acquire Sofie Biosciences for $945 million in cash to expand its reach in the U.S. radiopharmaceutical industry.
  • Sofie Biosciences is a contract manufacturing organization for positron emission tomography radiopharmaceuticals, radioactive drugs that are used in medical imaging tests to visualize metabolic and molecular activity and to treat a range of diseases.
  • The deal gives GE HealthCare a U.S. manufacturing and distribution footprint for F18-labeled PET products, which have a 110-minute half-life and require time-sensitive production and distribution, BTIG analyst Ryan Zimmerman said in a note to clients.

Dive Insight:

Sofie Biosciences will become part of GE HealthCare’s pharmaceutical diagnostics business, PDx, when the deal closes, which is expected in the first half of 2027.

GE HealthCare said it will continue to expand access to its existing proprietary F18 radiopharmaceutical products and advance a pipeline of new products, both through Sofie Biosciences and PDx’s other CMO partners across the U.S.

Sofie Biosciences, meanwhile, will remain an independent manufacturing partner to its customers and supply its existing portfolio, including products from other radiopharmaceutical providers. Sofie Biosciences has a U.S. network of 15 CMO sites. 

BTIG’s Zimmerman said the added manufacturing and distribution capacity could help reduce bottlenecks in the radiopharmaceutical adoption cycle.

GE HealthCare will also gain U.S. rights to FAPI-74, a pipeline pan-cancer PET radiotracer for which it holds rights outside the U.S.

Sofie Biosciences already manufactures GE HealthCare’s Flyrcado F18 injection product.

“As part of GE HealthCare, Sofie Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities,” Kevin O'Neill, CEO of GE HealthCare’s PDx business, said in a statement.

The acquisition is expected to contribute to GE HealthCare’s revenue growth and adjusted earnings per share in the first full year of ownership, the company said.

来源:BioPharma Dive · biopharmadive.com